CO2023009994A2 - Mutaciones en regiones constantes de anticuerpos caninos - Google Patents

Mutaciones en regiones constantes de anticuerpos caninos

Info

Publication number
CO2023009994A2
CO2023009994A2 CONC2023/0009994A CO2023009994A CO2023009994A2 CO 2023009994 A2 CO2023009994 A2 CO 2023009994A2 CO 2023009994 A CO2023009994 A CO 2023009994A CO 2023009994 A2 CO2023009994 A2 CO 2023009994A2
Authority
CO
Colombia
Prior art keywords
mutations
constant regions
canine antibodies
canine
antibodies
Prior art date
Application number
CONC2023/0009994A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Sandra Ann Marie Lightle
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2023009994A2 publication Critical patent/CO2023009994A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos caninos y usos de estas. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo canino para mejorar varias características.
CONC2023/0009994A 2021-01-28 2023-07-27 Mutaciones en regiones constantes de anticuerpos caninos CO2023009994A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28
PCT/US2022/014146 WO2022165067A2 (en) 2021-01-28 2022-01-27 Mutations in canine antibody constant regions

Publications (1)

Publication Number Publication Date
CO2023009994A2 true CO2023009994A2 (es) 2023-08-09

Family

ID=80786846

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0009994A CO2023009994A2 (es) 2021-01-28 2023-07-27 Mutaciones en regiones constantes de anticuerpos caninos

Country Status (13)

Country Link
US (1) US20240059777A1 (es)
EP (1) EP4284825A2 (es)
JP (1) JP2024505072A (es)
KR (1) KR20230136604A (es)
CN (1) CN116802205A (es)
AU (1) AU2022214843A1 (es)
CA (1) CA3207285A1 (es)
CL (1) CL2023002202A1 (es)
CO (1) CO2023009994A2 (es)
EC (1) ECSP23057156A (es)
IL (1) IL304522A (es)
TW (1) TW202246318A (es)
WO (1) WO2022165067A2 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Also Published As

Publication number Publication date
JP2024505072A (ja) 2024-02-02
AU2022214843A1 (en) 2023-07-20
US20240059777A1 (en) 2024-02-22
CN116802205A (zh) 2023-09-22
CL2023002202A1 (es) 2024-01-12
WO2022165067A3 (en) 2022-09-22
TW202246318A (zh) 2022-12-01
AU2022214843A9 (en) 2024-05-16
CA3207285A1 (en) 2022-08-04
KR20230136604A (ko) 2023-09-26
EP4284825A2 (en) 2023-12-06
IL304522A (en) 2023-09-01
ECSP23057156A (es) 2023-08-31
WO2022165067A2 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA202092847A1 (ru) Антитела к cd3 и их применение
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201891040A1 (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
CO2019010975A2 (es) Anticuerpos anti-par2 y usos de los mismos
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
ECSP23030271A (es) Variantes de anticuerpos caninos
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA201990978A1 (ru) Антитела против pd-1
ECSP23057156A (es) Mutaciones en regiones constantes de anticuerpos caninos
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
ECSP23030307A (es) Variantes de anticuerpos felinos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA201992186A1 (ru) Антитела к par2 и пути их применения
EA202192418A1 (ru) Способы лечения al-амилоидоза
TWD200747S (zh) 髮夾
EA201992885A1 (ru) Антитела, специфически связывающиеся с pd-1, и способы их применения